Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, ...

Atea has struggled to demonstrate bemnifosbuvir’s COVID potential in the past, including in a phase 2 trial back in the midst ...

Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene ...

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

On the efficacy issue, Merck told the meeting ... a temporary EUA until another oral antiviral candidate becomes available. The lack of data for the drug against the emerging Omicron variant ...

Seres Therapeutics' financial moves, potential drug developments, and investment appeal for speculative buyers in the biotech ...

Health Canada says it's still reviewing data on an antiviral COVID-19 drug that ... available" from pharmaceutical company Merck on their drug molnupiravir, considered the first pill to ...

The new start product of Merck is Keytruda, a cancer drug (monoclonal antibody), with sales growing ... The pandemic also boosted the sale of the antiviral pill Paxlovid by another $20B. But Pfizer is ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck (MRK.N), opens new tab said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...